Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Lupin Ltd: Emerging Strong - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Dec 18, 2001

    Lupin Ltd: Emerging Strong

    Last year, Lupin Chemicals and Lupin Laboratories merged to create a giant entity, Lupin Ltd., with sales turnover in excess of Rs 9 bn. The merger has helped the company in consolidating its leadership position in the anti –TB market. Further, the company is taking strides to become a recognized global player in the Cephalosporin (new generation anti-infectives) and is now considering research as a new thrust area.

    Lupin Chemicals manufactured Rifampicin while Lupin Laboratories manufactured Ethambutol. Together both these molecules command almost the entire anti-TB market. The consolidation helped the company in becoming a world leader in the anti-TB market, with a market share of more than 40% in the domestic anti-TB market, which is estimated at Rs 3.3 bn. In a segment, which registered, de-growth in last two years, Lupin recorded a double-digit growth in this segment.

    A higher incidence of HIV in the developed nations has resulted in significant rise in TB cases worldwide. Further, with global agencies like WHO funding anti-TB drugs, the global market is expected to grow considerably after witnessing a plateau. Lupin plans to enter into US$550 m global anti-TB market and is creating a manufacturing facility at Aurangabad with a capital outlay of Rs 200 m, complying with the US FDA specifications. Lupin aims to achieve more than 50% global market share in the anti-TB segment.

    The new thrust area for the company is Cephalosporins. Lupin has just commenced a state of art US FDA approved oral Cephalosporin bulk active plant. Cephalosporin enjoys global sales of US $ 11 bn. Several combinations of Cephalosporins, injectable and orals are going off patent. This provides the company good opportunity to develop competencies and launch these products in the generics market.

    Lupin plans to market its Cefotaxime Sodium in the US through its US partner, American Pharmaceutical Partners (APP). Cefotaxime formulations have reported sales of US$ 100 m in the year 2000. Lupin will supply the bulk drug to APP who in turn will formulate and market the product in the US. The company expects to achieve sales of US$ 14 m (Rs 680 m) in the first year of launch. The company has identified four other anti-infective molecules whose patents expire in 2002.

    The company is also aggressively launching new products to reduce its therapeutic segment dependence. The company has launched new products in cardiovascular, cephalosporin and herbal segments with plans to launch 40 new products in the current year. Lupin also plans to become a dominant player in the phytochemistry (alternative medicine) segment and has launched a range of products. The company has recently launched 3 herbal products namely: Anxicalm for anxiety, J.Wort for depression and Fibril Rich for the regulation of bowel movement.

    Though late, Lupin is now recognizing R&D as a thrust area. The company has established state-of-the-art R&D centre spread over an area of 19 acres at Pune. Lupin has 6 molecules in the pipeline and has plans to file 4 ANDA and 2 INDA in FY02 in the area of neurology, asthma, dermatology, herbal medicines and NDDS (New Drug Delivery System) in Cephalosporins.

    The merger has helped Lupin to catapult its position in the league of few Indian pharma companies with Rs 10 bn plus mark. However, company lacks presence in specialty pharma segment and both the company’s key segments (anti-TB and Cephalosporin) are highly price competitive and margins are unlikely to be lucrative. Hence, Lupin would have to push hard to drive growth in the domestic market. In the exports front, though the company is taking the right steps, it seems to be a bit late in cashing on the generic opportunity as it lacks an ANDA pipeline. Even on the exports front, the company would face competition from players from domestic pharma majors.

    However, the company seems to be rushing to make up for being a late entrant. To summarize, though the road ahead would not be smooth and easy, the company seems to have right plans in place. At the current market price of Rs 115, the stock trades at 7.6x FY01 earnings.



    Equitymaster requests your view! Post a comment on "Lupin Ltd: Emerging Strong". Click here!


    More Views on News

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

    May 29, 2017

    Currency fluctuation and one time provision impacts operating margins.

    Lupin: US Business Drives Growth (Quarterly Results Update - Detailed)

    Mar 8, 2017

    Lupin has announced its 3QFY17 results. Net sales have grown by 31.5% YoY and net profits have surged by 20.7% YoY. Here is our analysis of the results.

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    More Views on News

    Most Popular

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

    Aug 10, 2017

    Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    Bitcoin Continues Stellar Rise(Chart Of The Day)

    Aug 10, 2017

    Bitcoin hits an all-time high, is there more upside left?

    5 Steps To Become Financially Independent(Outside View)

    Aug 16, 2017

    Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 22, 2017 03:03 PM


    • Track your investment in LUPIN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks


    Compare Company With Charts